



EU Disease Lens' brings visibility and insight into the most critical diseases

INTERACTIVE DATA DASHBOARD AGGREGATES AND DISPLAYS EUROPEAN HEALTH DATA ACROSS 15 MAJOR DISEASE AREAS AND 28 COUNTRIES

Brussels, Belgium, 24 March 2015 – The Janssen Health Policy Centre (Janssen Pharmaceutica NV) today unveiled an innovative, first-of-its-kind digital dashboard that allows to explore and compare data from 15 major diseases across the 28 EU member states.

Free and intuitive, the EU Disease Lens is the latest initiative by Janssen's Health Policy Centre to inform and encourage public and policy dialogue around key health issues facing Europe today. It offers access to a single platform that aggregates disease data from across the most credible public sources including the World Health Organisation (WHO) and the European Commission.

The EU Disease Lens is unique in that it provides the ability to analyse, from within a single dashboard, rich data on the most prevalent diseases affecting EU citizens: including Tuberculosis (TB), Diabetes, Hepatitis C, HIV, Schizophrenia, Depression, Alzheimer, Psoriasis, Ulcerative Colitis, Crohn's disease, Multiple Myeloma and Mantle Cell Lymphoma as well as widespread forms of cancer such as Prostate and Chronic Lymphoid Leukaemia. Other key features of the tool include statistics about:

- **Global R&D Pipeline**
- **Latest New Drug Approvals in the EU**
- **Disease Data by EU Member State**
- **Epidemiological Data Comparison**
- **Prevalence Ratio (%)**
- **Total Number of Patients Suffering from the Disease**
- **Total DALYs (Disability Adjusted Life Year) (per year)**



The launch of the EU Disease Lens, coinciding with World Tuberculosis Day, follows the WHO's 2014 pledge to reduce mortality from TB by 95% by 2035.

"Public health policy cannot be properly made without the availability of the relevant data. Since no single source of information was available, we wanted to propose a unique initiative", says Beatrice Tardieu, Director at Janssen's Health Policy Centre. "With this innovative tool, the healthcare community can keep abreast of the most credible publically-available disease data sources. We hope this will foster learning about the prevalence of major diseases in an engaging and interactive format fuelled by real-world data".

Access to the EU Disease Lens is available for free from today at the following link: <http://www.diseaselens.com/>. The information provided in the EU Disease Lens is designed to be educational and is not intended to make treatment recommendations.

About Janssen Health Policy Centre

The Janssen Health Policy Centre exists to increase collaboration with public and private healthcare partners to challenge perspectives and work together to address the most serious health issues facing society. By fostering close partnerships and alliances with other industry players, the academic world and public health organisations, our Janssen experts explore ways to collaborate more broadly and efficiently to secure better patient outcomes. For more information, please see: <http://www.janssen-emea.com/hpc/health-welcome>

About Janssen

Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency. More information can be found on www.janssen-emea.com. Follow us on www.twitter.com/janssenEMEA for our latest news.



Contact details

Béatrice TARDIEU

Janssen Health Policy Center

Email: btardieu@its.jnj.com

Phone +33681449600